Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05509387

Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
42 (estimated)
Sponsor
Baycrest · Academic / Other
Sex
All
Age
50 Years – 90 Years
Healthy volunteers
Not accepted

Summary

There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.

Conditions

Interventions

TypeNameDescription
DEVICEtranscranial direct current stimulation and naming trainingParticipants will receive mild stimulation or no stimulation along with naming training

Timeline

Start date
2022-09-01
Primary completion
2025-12-31
Completion
2026-12-31
First posted
2022-08-22
Last updated
2024-08-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05509387. Inclusion in this directory is not an endorsement.